Skip to main content
Journal cover image

Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era

Publication ,  Conference
Clark, JI; Wong, MK; Daniels, GA; Kaufman, HL; McDermott, DF; Morse, MA; Aung, S
Published in: BJU INTERNATIONAL
October 1, 2014

Duke Scholars

Published In

BJU INTERNATIONAL

EISSN

1464-410X

ISSN

1464-4096

Publication Date

October 1, 2014

Volume

114

Start / End Page

5 / 5

Location

Chicago, IL

Publisher

WILEY-BLACKWELL

Conference Name

13th International Kidney Cancer Symposium

Related Subject Headings

  • Urology & Nephrology
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Clark, J. I., Wong, M. K., Daniels, G. A., Kaufman, H. L., McDermott, D. F., Morse, M. A., & Aung, S. (2014). Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era. In BJU INTERNATIONAL (Vol. 114, pp. 5–5). Chicago, IL: WILEY-BLACKWELL.
Clark, Joseph I., Michael K. Wong, Gregory A. Daniels, Howard L. Kaufman, David F. McDermott, Michael A. Morse, and Sandra Aung. “Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era.” In BJU INTERNATIONAL, 114:5–5. WILEY-BLACKWELL, 2014.
Clark JI, Wong MK, Daniels GA, Kaufman HL, McDermott DF, Morse MA, et al. Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era. In: BJU INTERNATIONAL. WILEY-BLACKWELL; 2014. p. 5–5.
Clark JI, Wong MK, Daniels GA, Kaufman HL, McDermott DF, Morse MA, Aung S. Extension of survival in patients with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2) immunotherapy in the post 2006 targeted therapy era. BJU INTERNATIONAL. WILEY-BLACKWELL; 2014. p. 5–5.
Journal cover image

Published In

BJU INTERNATIONAL

EISSN

1464-410X

ISSN

1464-4096

Publication Date

October 1, 2014

Volume

114

Start / End Page

5 / 5

Location

Chicago, IL

Publisher

WILEY-BLACKWELL

Conference Name

13th International Kidney Cancer Symposium

Related Subject Headings

  • Urology & Nephrology
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1103 Clinical Sciences